Universidad Peruana Cayetano Heredia

Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution

Mostrar el registro sencillo del ítem

dc.contributor.author García Lescano, Héctor Hugo
dc.contributor.author Del Brutto, Oscar H.
dc.date.accessioned 2019-01-25T16:59:36Z
dc.date.available 2019-01-25T16:59:36Z
dc.date.issued 2017
dc.identifier.uri https://hdl.handle.net/20.500.12866/4872
dc.description.abstract Antiparasitic agents against Taenia solium cysticercosis have been in use since 1979, although its use has been questioned on the basis that cysts would die naturally and thus treatment-induced inflammation is unnecessary. In addition, isolated reports have also questioned whether neurocysticercosis (NCC) is a cause of epilepsy. After more than three and a half decades, a large body of evidence is available. Little if any doubt exists about NCC as a cause of seizures - NCC is consistently associated with seizures when appropriate groups are compared, and in a large subset of cases, seizure semiology correlates with the anatomical location of lesions. Cyst degeneration and the subsequent inflammatory reaction increase seizure expression, although patients with non-inflamed cysts may have seizures, as do patients with long-standing, not inflamed calcified scars. Assessment of the evidence on cysticidal efficacy, safety, and the impact of cyst destruction in decreasing seizures leads to the conclusion that the benefits of antiparasitic treatment in parenchymal brain cysticercosis clearly outweigh the risks, and have provided substantive evidence of the role of NCC as a cause of seizures and epilepsy. Antiparasitic therapy should be considered a primary option in the management of patients with live or degenerating brain NCC cysts. This article is part of a Special Issue entitled "Neurocysticercosis and Epilepsy". en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Epilepsy and Behavior
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Female en_US
dc.subject Humans en_US
dc.subject Treatment Outcome en_US
dc.subject Cysts en_US
dc.subject Anticestodal Agents en_US
dc.subject Albendazole en_US
dc.subject Cysticercosis en_US
dc.subject Epilepsy en_US
dc.subject Neurocysticercosis en_US
dc.subject Praziquantel en_US
dc.subject Seizures en_US
dc.subject Taenia solium en_US
dc.subject Albendazole/therapeutic use en_US
dc.subject Antiparasitic Agents/therapeutic use en_US
dc.subject Brain/pathology en_US
dc.subject Epilepsy/drug therapy/parasitology en_US
dc.subject Inflammation/complications en_US
dc.subject Neurocysticercosis/complications/drug therapy en_US
dc.subject Praziquantel/therapeutic use en_US
dc.subject Seizures/drug therapy/etiology en_US
dc.title Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1016/j.yebeh.2017.03.013
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.25
dc.relation.issn 1525-5069


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas